Serially increasing change in lipoprotein(a) concentration has predictive value in acute vascular events

Annals of Clinical Biochemistry

Volumn 42, Issue 4, 2005, Pages 285-291

  Hong, Soon Jun ^a   Seo, Hong Seog ^a   Park, Chang Gyu ^a   Rha, Seung Woon ^a   Oh, Dong Joo ^a   Ro, Young Moo ^a  

^a Korea University Ansan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOCYTE; LIPOPROTEIN BLOOD LEVEL; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; STABLE ANGINA PECTORIS; STROKE;

ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 21844470990     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563054255560     Document Type: Article

References (35)

1. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-10
2. Akita H, Matsubara M, Shibuya H, Fuda H, Chiba H. Effect of ageing on plasma lipoprotein(a) levels. Ann Clin Biochem 2002; 39: 237-40
3. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95-101
4. Craig WY, Ledue TB. Lipoprotein(a) and the acute phase response. Clin Chim Acta 1992; 210: 231-2
5. Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672-9
6. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111-26
7. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto Jr AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-65
9. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003
10. von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-5
11. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84
12. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204
13. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942-5
14. Molgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 1992; 12: 895-901
15. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994; 154: 801-6
16. Cantin B, Moorjani S, Dagenais GR, Lupien PJ. Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Quebec Cardiovascular Study). Am J Cardiol 1995; 75: 1224-8
17. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9
18. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19
19. Kostner KM, Kostner GM. Lipoprotein(a): still an enigma? Curr Opin Lipidol 2002; 13: 391-6
20. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-25
21. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67
22. Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 1997; 45: 559-68
23. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9
24. Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen? QJM 2000; 93: 75-84
25. Kostner GM, Bihari-Varga M. Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans? Eur Heart J 1990; 11: 184-9
26. Jamieson DG, Usher DC, Rader DJ, Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 1995; 147: 1567-74
27. Nielsen LB, Stender S, Jauhiainen M, Nordestgaard BG. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with non-lesioned rabbit aorta. J Clin Invest 1996; 98: 563-71
28. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998; 97: 721-8
29. Takahashi A, Taniguchi T, Fujioka Y, Ishikawa Y, Yokoyama M. Effects of lipoprotein(a) and low density lipoprotein on growth of mitogen-stimulated human umbilical vein endothelial cells. Atherosclerosis 1996; 120: 93-9
30. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-2
31. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5
32. Noma A, Abe A, Maeda S, et al. Lp(a): an acute-phase reactant? Chem Phys Lipids 1994; 67-68: 411-7
33. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-9
34. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65
35. Hamano M, Saito M, Eto M, et al. Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. Ann Clin Biochem 2004; 41: 125-9